On Jun 07, 2018, the tribunal de grande instance of Paris issued a preliminary injunction against Teva’s generic of anti-hypertensive drug EXFORGE®.

As reported on “EP law blog”, the judge rejected all the invalidity arguments raised by Teva (double patenting, insufficiency, extension, obviousness). Teva’s generic had been put on the market in October 2017; therefore the court ordered Teva to pay Novartis more than €13,000,000 as an advance on damages.

Patent-in-suit was EP 2322174 entitled, “combined use of valsartan and calcium channel blockers for therapeutic purposes”. The EXFORGE®, which includes valsartan and amlodipine, is covered by EP 174.